



## **Webcast Alert: Aastrom Announces Conference Call to Discuss the Results from the U.S. Phase I/II Severe Fracture Trial**

ANN ARBOR, Mich., Oct 16, 2007 (BUSINESS WIRE) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast:

What: Aastrom Biosciences, Inc. Conference Call to Discuss the Results from the U.S. Phase I/II Severe Fracture Trial

When: Monday, October 22, 2007 at 9:00 am (EDT)

Where: <http://www.vcall.com/IC/CEPage.asp?ID=122247>

How: -- For live Internet access, simply log on to the web at the address above.

-- For phone access, interested parties should call toll-free (877) 407-9205 15 minutes before the start of the call to register and identify themselves as registrants of the "Aastrom Conference Call". Any registered caller on the toll-free line may ask for call operator for directions to be placed in the queue for the Question & Answer session. If calling from outside the U.S., please use the international phone number (201) 689-8054.

-- To download the podcast, simply log on to the web at the address above.

Contact: Investor Relations Department, (734) 930-5777 or [mail@aastrom.com](mailto:mail@aastrom.com)

If you are unable to participate during the live call, the webcast will be available for replay at <http://www.investorcalendar.com/> until January 22, 2008. Through November 1, 2007, the audio replay of the call will be available by dialing toll-free (877) 660-6853, or from outside the U.S. (201) 612-7415. When prompted on the phone, the account # is: 286, and the conference ID# is: 259045.

Aastrom is a leader in the development of autologous cell products for the repair or regeneration of human tissue. The Company's proprietary Tissue Repair Cell (TRC) Technology involves the use of a patient's own cells to manufacture products to treat a range of chronic diseases and serious injuries affecting bone, vascular, cardiac, and neural tissues. Aastrom's TRC-based products contain increased numbers of stem and early progenitor cells, produced from a small amount of bone marrow collected from the patient. The TRC Technology platform has positioned Aastrom to advance multiple products into clinical development. Currently, the Company has a bone regeneration product in Phase III development for the treatment of osteonecrosis of the femoral head (called the ON-CORE trial), a vascular regeneration product in Phase IIb development for the treatment of critical limb ischemia (called the RESTORE-CLI trial), and preclinical research programs targeting unmet needs in cardiac and neural health. Aastrom product candidates to treat osteonecrosis of the femoral head and dilated cardiomyopathy have been designated for orphan drug status by the FDA. For more information, visit Aastrom's website at [www.aastrom.com](http://www.aastrom.com). (astmc)

SOURCE: Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc.  
Investor Relations Department, 734-930-5777  
[mail@aastrom.com](mailto:mail@aastrom.com)

Copyright Business Wire 2007

News Provided by COMTEX